Theravance Biopharma (TBPH) Stock Price, News & Analysis

Company Overview

Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for respiratory disease and other serious conditions. The company’s work centers on therapies designed to address unmet needs in areas such as chronic obstructive pulmonary disease (COPD) and related respiratory disorders.

Its principal commercial product is YUPELRI (revefenacin), an inhaled long-acting muscarinic antagonist used as a once-daily maintenance treatment for COPD. YUPELRI is commercialized in collaboration with Viatris. Theravance also receives royalties associated with certain respiratory products developed through its collaboration with GlaxoSmithKline, including the products marketed as Trelegy Ellipta.

Theravance Biopharma was established in 2013 following the separation of its biopharmaceutical operations from Theravance, Inc. The company is headquartered in Dublin, Ireland, and relies on commercial and development partners to support the availability of its medicines in the United States and selected international markets. Rick E. Winningham has served as the company’s chief executive officer since its formation.

Key Stats

• Today's Range: $17.03 to $17.03
• 50-Day Range: $16.87 to $17.08
• 52-Week Range: $13.08 to $21.03
• Volume: N/A
• Average Volume: 680,323 shs
• Market Capitalization: $884.18 million
• P/E Ratio: 16.86
• Dividend Yield: N/A
• Price Target: $19.40
• Consensus Rating: Hold

Theravance Biopharma Stock Analysis - MarketRank™

Theravance Biopharma scored higher than 36% of companies evaluated by MarketBeat, and ranked 740th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Hold

Consensus Rating

Theravance Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 8 hold ratings, and no sell ratings.

Upside Potential

Theravance Biopharma has a consensus price target of $19.40, representing about 13.9% upside from its current price of $17.03.

Amount of Analyst Coverage

Theravance Biopharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -48.08%

Earnings Growth

Earnings for Theravance Biopharma are expected to decrease by -48.08% in the coming year, from $1.56 to $0.81 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Theravance Biopharma is 16.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of Theravance Biopharma is 16.86, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.13.

Price to Book Value per Share Ratio

Theravance Biopharma has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.52% of the float of Theravance Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Theravance Biopharma has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Theravance Biopharma has recently increased by 4.21%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Theravance Biopharma does not currently pay a dividend.

Dividend Growth

Theravance Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for TBPH on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $226,737.00 in company stock.

Percentage Held by Insiders

7.65% of the stock of Theravance Biopharma is held by insiders.

Percentage Held by Institutions

99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TBPH
• Previous Symbol: NASDAQ:TBPHV
• CIK: 1583107
• Web: www.theravance.com
• Phone: (650) 808-6000
• Fax: N/A
• Employees: 110
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Theravance Biopharma: $19.40
• High Price Target: $27.00
• Low Price Target: $15.00
• Potential Upside/Downside: +13.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.01
• Trailing P/E Ratio: 16.86
• Forward P/E Ratio: 10.92
• P/E Growth: N/A
• Net Income: $105.89 million
• Net Margins: 51.58%
• Pretax Margin: 56.48%
• Return on Equity: -0.77%
• Return on Assets: -0.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.54
• Quick Ratio: 13.54

Sales & Book Value

• Annual Sales: $104.31 million
• Price / Sales: 8.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.86 per share
• Price / Book: 2.91

Miscellaneous

• Outstanding Shares: 51,919,000
• Free Float: 47,947,000
• Market Cap: $884.18 million
• Optionable: Optionable
• Beta: 0.25